Protagonist Therapeutics Files 8-K

Ticker: PTGX · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1377121

Sentiment: neutral

Topics: sec-filing, 8-k, routine-reporting

TL;DR

Protagonist Therapeutics filed a routine 8-K on March 3, 2025, no major news.

AI Summary

On March 3, 2025, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial transactions or material events beyond routine reporting were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates routine corporate reporting by Protagonist Therapeutics, Inc. to the SEC, without immediate disclosure of significant new events.

Risk Assessment

Risk Level: low — The filing appears to be a standard disclosure without any immediate indication of significant financial or operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of March 3, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing is dated March 3, 2025.

In which state is Protagonist Therapeutics, Inc. incorporated?

Protagonist Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Protagonist Therapeutics, Inc.?

The Commission File Number for Protagonist Therapeutics, Inc. is 001-37852.

What is the business address of Protagonist Therapeutics, Inc.?

The business address of Protagonist Therapeutics, Inc. is 7707 Gateway Blvd., Suite 140, Newark, California 94560-1160.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Protagonist Therapeutics, Inc (PTGX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing